Polfa Tarchomin invests in a new plant and new products

APA - Austria Presse Agentur
opublikowano: 27-11-2006, 13:33

Warsaw (Puls Biznesu) – Polfa wants to catch up Bioton, the country’s leading insulin producer. It is going to win new markets in Europe and Persian Gulf countries.

Warsaw (Puls Biznesu) – Polfa wants to catch up Bioton, the country’s leading insulin producer. It is going to win new markets in Europe and Persian Gulf countries.


Polfa Tarchomin planned to have 3 percent of the Polish market of human insulin worth PLN 500m (EUR 130.5m). The company, which launched this product in March, will have had 2 percent of the market, however. The management explains this with delays in registering. Bioton controls 24 percent of the market.

“We want to develop sales and capacity. We think about the European and Arab market but next year at the earliest”, Dariusz Sobczak, Polfa Tarchomin CEO said.


So far, the company has produced only animal insulin, which is more expensive. Polfa Tarchomin is a leader here and it exports the insulin to Belorussia or Vietnam. The company plans farther expansion in China. Polfa has started to sell there this year. This market constitutes 1.5 percent of its exports. Next year, the market should double.


Polfa Tarchomin has 140 products. In the second half of next year, it is going to build a new pill plant worth PLN 120-130m. At the end of this year, the company wants to generate similar results as last year, or PLN 5m of net income against at least PLN 290m of sales. The company employs 2,200 people today.

(PLN 1 = EUR 0.261)

© ℗
Rozpowszechnianie niniejszego artykułu możliwe jest tylko i wyłącznie zgodnie z postanowieniami „Regulaminu korzystania z artykułów prasowych” i po wcześniejszym uiszczeniu należności, zgodnie z cennikiem.

Podpis: APA - Austria Presse Agentur